4//SEC Filing
Camaisa Allan 4
Accession 0001493152-25-028030
CIK 0001855485other
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 7:37 PM ET
Size
6.5 KB
Accession
0001493152-25-028030
Insider Transaction Report
Form 4
Camaisa Allan
DirectorCEO, President and Chairman10% Owner
Transactions
- Sale
Common Stock
2025-12-12$1.46/sh−850$1,237→ 76,952 total(indirect: By LLC)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected for estate and tax planning purposes by AJC Capital, LLC ("AJC"). The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer.
- [F2]Includes (i) 6,394 shares of Common Stock directly held by Allan Camaisa, (ii) 19,860 shares of Common Stock held by AJC, and (iii) 50,698 shares of Common Stock held by Jamir Trust.
- [F3]Does not include, (i) 1,526 shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by Mr. Camaisa, (ii) 3,915 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, and (iii) 22,887 shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by AJC.
- [F4]Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa is deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust.
- [F5]All share and share related information gives retrospective effect to the 1-for-12 reverse stock split effective on August 4, 2025.
Documents
Issuer
Calidi Biotherapeutics, Inc.
CIK 0001855485
Entity typeother
Related Parties
1- filerCIK 0001990674
Filing Metadata
- Form type
- 4
- Filed
- Dec 15, 7:00 PM ET
- Accepted
- Dec 16, 7:37 PM ET
- Size
- 6.5 KB